Published 19 days ago • loading... • Updated 19 days ago

Cizzle Bio Expands Global Reach with Cayman Islands Launch of Biomarker Blood Tests for Lung and Gastric Cancers

Cizzle Bio announced on May 28, 2025, it has partnered with Doctors Hospital in George Town, Cayman Islands, to launch biomarker tests for lung and gastric cancers.
The partnership leverages Cizzle Bio's exclusive rights to the CIZ1B lung cancer test across North America and the Caribbean region, along with a global license for their DEX-G2 gastric cancer test.
Doctors Hospital, founded in 2000 and a leading private-sector provider in the Caribbean, will use these tests in its clinical laboratory to support earlier and more accurate cancer detection.
Bill Behnke, CEO of Cizzle Bio, expressed excitement about collaborating with Doctors Hospital to offer their biomarker blood tests to individuals in the Caribbean, while David E. Pellow highlighted the hospital’s dedication to utilizing advanced diagnostic tools for earlier detection and improved patient care.
The collaboration aims to improve patient outcomes by enabling minimally invasive, accurate detection methods and aligns with Cizzle Bio's strategy to expand innovative cancer diagnostics internationally and in the U.S.

Insights by Ground AI

Does this summary seem wrong?

17 Articles

All

Left

Center

Right

The Dispatch

+16 Reposted by 16 other sources

Lean Right

Cizzle Bio Expands Global Reach with Cayman Islands Launch of Biomarker Blood Tests for Lung and Gastric Cancers

GEORGE TOWN, Cayman Islands, May 28, 2025 /PRNewswire/ -- Cizzle Bio, Inc., a biotechnology company pioneering innovative biomarker blood tests for early detection of lung and gastric cancers, has announced an agreement with Doctors Hospital in the Cayman Islands to…

19 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year